Skip to main content
Sign In
 

Charles Daley, MD

Professor


 
 

Head, Division of Mycobacterial and Respiratory Diseases

National Jewish Health
Phone: 303-398-1667
Fax: 303-398-1780
E-mail: daleyc@njc.org
Address:Campus Box A004
1400 Jackson Street, Room J204
Denver, CO

 

Medical Schoool
University of Mississippi Medical School, MD, 1979-1983

Residencies
University of California, San Francisco, Internal Medicine, 1983-1986
University of California, San Francisco, Chief Resident, 1986-1987

Fellowship
University of California, San Francisco, Pulmonary and Critical Care Medicine, 1988-1991

 

Mycobacterial (TB/nontuberculous) and Respiratory Infections, Infectious Diseases, Allergic Pulmonary Bronchial Aspergillosis, Bronchiectasis, Drug-resistant Tuberculosis, Fungal Lung Disease, Immune Deficiencies, Infectious Diseases (Chronic Respiratory Infections), Nontuberculous Mycobacterial Infections, Sinusitis, Tuberculosis, Respiratory Infections

My research has focused on clinical and epidemiological studies of tuberculosis and nontuberculous mycobacterial infections. In particular, I am interested in the molecular epidemiology of these infections and how we can better elucidate issues relevant to the transmission and pathogenesis of these important diseases. I am also interested in studying new diagnostic tests and new drugs and treatment regimens.

In addition to my research I am very committed to medical education and training individuals to do clinical and epidemiologic research. I hope to develop a training program in mycobacterial diseases here at National Jewish.

 

1) Marras TK, Gonzalez L, Daley CL. Predictors of mortality in HIV-infected patients with pulmonary Mycobacterium kansasii. Am J Respir Crit Care Med 2004;170:793-798.

2) Jasmer RM, Seaman C, Gonzalez LC, Kawamura LM, Daley CL. Tuberculosis treatment outcomes: directly observed therapy compared with self-administered therapy. Am J Respir Crit Care Med 2004;170:561-566.

3) Ziv E, Daley CL, Blower S. Potential public health impact of tuberculosis vacccines. Emerg Infect Dis 2004;10:1529-1535.

4) Jasmer RM., Snyder DC, Saukkonen JJ, Blumberg H, Hopewell PC, Bernardo J, King MD, Kawamura LM, Daley CL, for the Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators. Short-Course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: A Cost-Effectiveness analysis based on a multicenter clinical trial. CID 2004; 38: 363-9.

5) Ong A, Creasman J, Hopewell PC, Gonzalez L, Wong M, Jasmer RM, Daley CL. A molecular epidemiologic assessment of extrapulmonary tuberculosis in San Francisco. CID 2004;38: 25-31.